论文部分内容阅读
自1997年9月以来我们使用降纤酶治疗脑梗塞患者138例,并进行了临床对照观察。 1 临床资料 1.1 一般资料 治疗组138例,其中男63例,女75例,年龄51～82岁,平均66.5岁。对照组138例,其中男65例,女73例,年龄49～87岁,平均67岁。两组病例全部符合1995年全国第四届脑血管病会议提出的脑梗塞诊断标准,并按“脑卒中患者临床神经功能缺损程度评分标准”及其“伴发疾病的评分”和“既往史的评分标准”进行评分,两组间平均积分无显著差异(P>0.05),均无治疗药物禁忌症及严重心、肝、肾损害。 1.2 治疗方法 治疗组使用降纤酶治疗,首次用10单位加入生理盐水或5％葡萄糖液250ml静脉滴注,以后隔日用5单位降纤酶加入上述液体中静脉滴注,使用3次为1疗程,共20单位,每次滴注时间均超过1小时以上,在间隔日及降纤酶治疗后使用血塞通400mg加入生理盐水或5％葡萄糖液250ml静脉滴注,共14天,对照组每日用血塞通400mg加入生理盐水或5％
Since September 1997, we used defibrase to treat 138 patients with cerebral infarction and conducted clinical control observation. 1 Clinical data 1.1 General Information Treatment group 138 cases, 63 males and 75 females, aged 51 to 82 years, mean 66.5 years. The control group of 138 patients, including 65 males and 73 females, aged 49 to 87 years, mean 67 years. The two groups of patients all meet the diagnostic criteria of cerebral infarction proposed by the Fourth National Conference on Cerebrovascular Disease in 1995. According to the score of clinical neurological deficit in stroke patients and its score of concomitant diseases and the past history Grading standards ". There was no significant difference between the two groups (P> 0.05). There were no contraindications to treatment with drugs and severe heart, liver and kidney damage. 1.2 The treatment group using defibrase treatment, the first time with 10 units by adding saline or 5% glucose solution 250ml intravenous infusion, followed by 5 units of defibrase added to the above liquid intravenous infusion, the use of 3 times for a course of treatment , A total of 20 units, each infusion time of more than 1 hour above the interval and defibrase after the use of Xuesaitong 400mg saline or 5% glucose 250ml intravenous infusion of a total of 14 days in the control group each Daily Xuesaitong 400mg added saline or 5%